71 related articles for article (PubMed ID: 28274549)
1. Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration.
Kinai E; Gatanaga H; Mizushima D; Nishijima T; Aoki T; Genka I; Teruya K; Tsukada K; Kikuchi Y; Oka S
J Infect Chemother; 2017 May; 23(5):259-264. PubMed ID: 28274549
[TBL] [Abstract][Full Text] [Related]
2. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial.
Meier C; Beat M; Guglielmetti M; Christ-Crain M; Staub JJ; Kraenzlin M
Osteoporos Int; 2004 Mar; 15(3):209-16. PubMed ID: 14727010
[TBL] [Abstract][Full Text] [Related]
3. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
[TBL] [Abstract][Full Text] [Related]
4. [The effects of levothyroxine replacement therapy on bone and mineral metabolism in patients with hypothyroidism].
Chai R; Ye Z; Zhan Z; Liu W; Yu M; Liu Y
Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):18-21. PubMed ID: 11798620
[TBL] [Abstract][Full Text] [Related]
5. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
[TBL] [Abstract][Full Text] [Related]
6. Eating restraint is negatively associated with biomarkers of bone turnover but not measurements of bone mineral density in young women.
Nickols-Richardson SM; Beiseigel JM; Gwazdauskas FC
J Am Diet Assoc; 2006 Jul; 106(7):1095-101. PubMed ID: 16815126
[TBL] [Abstract][Full Text] [Related]
7. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
8. Long-term use of protease inhibitors is associated with bone mineral density loss.
Kinai E; Nishijima T; Mizushima D; Watanabe K; Aoki T; Honda H; Yazaki H; Genka I; Tanuma J; Teruya K; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
AIDS Res Hum Retroviruses; 2014 Jun; 30(6):553-9. PubMed ID: 24494779
[TBL] [Abstract][Full Text] [Related]
9. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
10. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
11. Relationship of bone turnover to bone density and fractures.
Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
[TBL] [Abstract][Full Text] [Related]
12. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone favorably affects bone turnover and bone mineral density in patients with short bowel syndrome undergoing intestinal rehabilitation.
Tangpricha V; Luo M; Fernández-EstÃvariz C; Gu LH; Bazargan N; Klapproth JM; Sitaraman SV; Galloway JR; Leader LM; Ziegler TR
JPEN J Parenter Enteral Nutr; 2006; 30(6):480-6. PubMed ID: 17047171
[TBL] [Abstract][Full Text] [Related]
14. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
Dresner-Pollak R; Karmeli F; Eliakim R; Ackerman Z; Rachmilewitz D
Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
[TBL] [Abstract][Full Text] [Related]
15. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
17. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy.
Avgeri M; Papadopoulou A; Platokouki H; Douros K; Rammos S; Nicolaidou P; Aronis S
J Pediatr Hematol Oncol; 2008 Aug; 30(8):592-7. PubMed ID: 18799935
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation.
Shapses SA; Von Thun NL; Heymsfield SB; Ricci TA; Ospina M; Pierson RN; Stahl T
J Bone Miner Res; 2001 Jul; 16(7):1329-36. PubMed ID: 11450709
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
[TBL] [Abstract][Full Text] [Related]
20. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
